Distinct clinicopathologic clusters of persons with TDP-43 proteinopathy

• Published in: Acta neuropathologica Vol. 140; no. 5; pp. 659 - 674
• Main Authors: Katsumata, Yuriko, Abner, Erin L., Karanth, Shama, Teylan, Merilee A., Mock, Charles N., Cykowski, Matthew D., Lee, Edward B., Boehme, Kevin L., Mukherjee, Shubhabrata, Kauwe, John S. K., Kryscio, Richard J., Schmitt, Frederick A., Fardo, David W., Nelson, Peter T.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2020; Springer; Springer Nature B.V
• Subjects: Age; Age Factors; Aged; Aged, 80 and over; Algorithms; Alzheimer's disease; Amyloid; Aphasia; Appetite; Autopsy; Brain; Cluster Analysis; Cognitive ability; Death; Degeneration; Dementia; Dementia disorders; Emotional behavior; Encephalopathy; Female; Frontotemporal dementia; Frontotemporal Dementia - classification; Frontotemporal Dementia - pathology; Humans; Lewy bodies; Male; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Neurodegenerative diseases; Neuropathology; Neurosciences; Original Paper; Pathology; Phenotypes; Senile plaques; Single nucleotide polymorphisms; TDP-43 Proteinopathies - classification; TDP-43 Proteinopathies - pathology; Psychosis; Anxiety; Trajectory; DLB; Hallucinations; FTD
• ISSN: 0001-6322; 1432-0533; 1432-0533
• DOI: 10.1007/s00401-020-02211-0

To better understand clinical and neuropathological features of TDP-43 proteinopathies, data were analyzed from autopsied research volunteers who were followed in the National Alzheimer’s Coordinating Center (NACC) data set. All subjects ( n  = 495) had autopsy-proven TDP-43 proteinopathy as an inclusion criterion. Subjects underwent comprehensive longitudinal clinical evaluations yearly for 6.9 years before death on average. We tested whether an unsupervised clustering algorithm could detect coherent groups of TDP-43 immunopositive cases based on age at death and extensive neuropathologic data. Although many of the brains had mixed pathologies, four discernible clusters were identified. Key differentiating features were age at death and the severity of comorbid Alzheimer’s disease neuropathologic changes (ADNC), particularly neuritic amyloid plaque densities. Cluster 1 contained mostly cases with a pathologic diagnosis of frontotemporal lobar degeneration (FTLD-TDP), consistent with enrichment of frontotemporal dementia clinical phenotypes including appetite/eating problems, disinhibition and primary progressive aphasia (PPA). Cluster 2 consisted of elderly limbic-predominant age-related TDP-43 encephalopathy (LATE-NC) subjects without severe neuritic amyloid plaques. Subjects in Cluster 2 had a relatively slow cognitive decline. Subjects in both Clusters 3 and 4 had severe ADNC + LATE-NC; however, Cluster 4 was distinguished by earlier disease onset, swifter disease course, more Lewy body pathology, less neocortical TDP-43 proteinopathy, and a suggestive trend in a subgroup analysis ( n  = 114) for increased C9orf72 risk SNP rs3849942 T allele (Fisher’s exact test p value = 0.095). Overall, clusters enriched with neocortical TDP-43 proteinopathy (Clusters 1 and 2) tended to have lower levels of neuritic amyloid plaques, and those dying older (Clusters 2 and 3) had far less PPA or disinhibition, but more apathy. Indeed, 98% of subjects dying past age 85 years lacked clinical features of the frontotemporal dementia syndrome. Our study revealed discernible subtypes of LATE-NC and underscored the importance of age of death for differentiating FTLD-TDP and LATE-NC.